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Introduction:
Lafora disease (LD, OMIM #254789) is an autosomal recessive fatal epilepsy that is also classified as a glycogen storage disease (GSD). LBs are comprised of glucose connected by a-1,4-and a-1,6-linkages and synthesized by the same enzymes as glycogen. However, the glucose chains are longer, less 42 branched, and possess higher levels of covalent phosphate. 10 , 11 These characteristics Glycine, 10 g/L SOS) in 900 ml water]. Transfers were performed using a semi-dry turbo by two-way ANOVA and is measured against the PBS measurement from the same slice. *** is pS0.001, **** is pS0.0001.
Discussion:
The development of quantitative detection assays for new therapeutics is an essential aspect of pre-clinical and clinical research. This study focuses on VAL-0417, a 3E10-29 based cell penetrating AEF that utilizes pancreatic amylase to degrade LBs and treat LD. We developed an ELISA for VAL-0417 and provide initial preclinical data demonstrating 36 VAL-0417 delivery into WT and LD mice. generate independently. The mouse monoclonal anti-3E10 Fab is highly specific for the
